A newly published peer-reviewed study in Natural Product Research suggests that extracts from the stevia plant may upregulate GLP-1 activity in beta cells — the same hormone pathway targeted by medications like Ozempic, Wegovy, Mounjaro, and Zepbound. The findings have sparked interest, but experts urge caution before drawing comparisons to prescription GLP-1 drugs.
What the Study Found
The study, published in Natural Product Research, examined stevia plant extracts — specifically stevioside, a compound derived from Stevia rebaudiana — and their effects on beta cells. According to the research, the extracts were associated with upregulation of three key biological markers: INS1, TRPM5, and GLP-1 in beta cells. The study also explored how abiotic elicitation — a process of stressing the plant to enhance its bioactive compounds — could increase stevioside content in the plant itself.
GLP-1, or glucagon-like peptide-1, is the hormone that prescription medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are designed to mimic or amplify. The idea that a natural plant compound might influence the same pathway is scientifically noteworthy.
Important Context: Lab Findings vs. Real-World Treatment
It's critical for patients to understand the significant gap between a cell-based study and a clinically approved treatment. The research described in Natural Product Research examined effects in beta cells — meaning the findings come from a laboratory setting, not human clinical trials. There is no evidence presented in the source material that consuming stevia produces the same GLP-1 effects in humans as prescription medications do.
Prescription GLP-1 receptor agonists have undergone extensive, multi-phase clinical trials involving thousands of participants, with tightly controlled dosing and safety monitoring. A cell-level observation, while interesting, is a very early step in a long research process.
Key takeaway: This study shows stevia extracts may influence GLP-1-related markers in beta cells under lab conditions — but this is not evidence that eating stevia or taking stevia supplements replicates the effects of Ozempic, Wegovy, Mounjaro, or Zepbound in humans.
What This Means for Patients on GLP-1 Medications
If you are currently taking a GLP-1 medication, this study is not a reason to change your treatment plan. Stevia is widely used as a low-calorie sweetener and is generally recognized as safe, but no dosing, formulation, or clinical outcome data for humans is presented in this research. Patients should not interpret these findings as a substitute for or enhancement to their prescribed medication without speaking to their doctor first.
What to Watch Next
The findings from this Natural Product Research study may prompt further investigation into how plant-derived compounds interact with the GLP-1 pathway. Future research would need to move from cell-based studies into animal models and eventually human clinical trials before any meaningful conclusions about therapeutic benefit could be drawn. For now, this remains early-stage, exploratory science worth monitoring — but not acting on independently.
Frequently Asked Questions
As always, any changes to your GLP-1 treatment plan — including adding supplements — should be discussed with your prescriber or a qualified healthcare provider who knows your full medical history.
- Peer-reviewed journal article, 'Enhancement of stevioside by abiotic elicitation in Stevia rebaudiana and upregulation of INS1, TRPM5, and GLP-1 in β-cells via plant extracts,' Natural Product Research, date not specified in source material.